Physician profile
Melissa L Porter
NPI 1740414705
$4,582.03
in general payments reported to CMS, 2019-2025
32 companies · $656 in 2025
The $656 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $870 · 2022: $932 · 2023: $1,188 · 2024: $936 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $573.15 | 2023-2025 | Gemtesa, Orgovyx |
| Medtronic, INC. | $489.44 | 2022-2025 | Interstim, Nuro |
| Astellas Pharma US INC | $480.63 | 2021-2025 | Xtandi, Myrbetriq |
| Abbvie INC. | $414.87 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $321.16 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Myriad Genetic Laboratories, INC. | $273.63 | 2023-2024 | Prolaris |
| Dendreon Pharmaceuticals LLC | $254.20 | 2021-2024 | Provenge |
| Endo Pharmaceuticals INC. | $217.31 | 2021-2023 | Xiaflex, Aveed |
| Urovant Sciences INC | $216.54 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $201.35 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $173.94 | 2021-2025 | Lynparza |
| Novartis Pharmaceuticals Corporation | $110.99 | 2022-2025 | |
| Pfizer INC. | $95.91 | 2021-2025 | |
| Coloplast Corp | $94.64 | 2023-2025 | Speedicath, Porges Coloplast |
| 180 Medical, INC. | $81.95 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $73.78 | 2021-2023 | |
| Endo USA, INC. | $62.38 | 2024-2025 | Xiaflex |
| Myovant Sciences INC. | $60.20 | 2021-2022 | |
| Amgen INC. | $59.81 | 2021-2022 | |
| Janssen Biotech, INC. | $52.69 | 2023 | Erleada |
| Boston Scientific Corporation | $52.20 | 2021-2022 | |
| Teleflex LLC | $37.85 | 2023 | Urolift |
| Allergan, INC. | $27.48 | 2021 | |
| Rochester Medical Corporation | $26.16 | 2022 | |
| Antares Pharma, INC. | $22.51 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $20.34 | 2021 | |
| Telix Pharmaceuticals | $19.78 | 2024 | Illuccix |
| Immunitybio, INC. | $17.91 | 2024 | |
| Abc Home Medical Supply, INC. | $17.23 | 2023 | |
| Procept Biorobotics Corporation | $15.51 | 2023 | Aquabeam Robotic System |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2022 | |
| Travere Therapeutics, INC. | $2.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.